Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Golimumab

Abstract

Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Williams, R. O., Paleolog, E. & Feldmann, M. Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr. Opin. Pharmacol. 7, 412–417 (2007).

    CAS  Article  Google Scholar 

  2. 2

    Shealy, D. et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFα. Ann. Rheum. Dis. 66 (Suppl 2), 151 (2007).

  3. 3

    Zhou, H. et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J. Clin. Pharmacol. 47, 383–2396 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Food and Drug Administration. FDA labelling information. FDA web site [online] (2009).

  5. 5

    Lonberg, N. Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol. 20, 450–459 (2008).

    CAS  Article  Google Scholar 

  6. 6

    Smolen, J. S. et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374, 210–221 (2009).

    CAS  Article  Google Scholar 

  7. 7

    Keystone, E. C. et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann. Rheum. Dis. 68, 789–796 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Kavanaugh, A. et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60, 976–986 (2009).

    CAS  Article  Google Scholar 

  9. 9

    Inman, R. D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58, 3402–3412 (2008).

    CAS  Article  Google Scholar 

  10. 10

    Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N. Engl. J. Med. 343, 1594–1602 (2000).

    CAS  Article  Google Scholar 

  11. 11

    van der Heijde, D. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54, 1063–1074 (2006).

    CAS  Article  Google Scholar 

  12. 12

    Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

    CAS  Article  Google Scholar 

  13. 13

    Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319–3329 (2008).

    CAS  Article  Google Scholar 

  14. 14

    Wallis, R. S. Infectious complications of tumor necrosis factor blockade. Curr. Opin. Infect. Dis. 22, 403–409 (2009).

    CAS  Article  Google Scholar 

  15. 15

    Kay, J. et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 964–975 (2008).

    CAS  Article  Google Scholar 

  16. 16

    Visvanathan, S. et al. E-selectin, interleukin 18, serum amyloid A, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J. Rheumatol. 36, 1371–1379 (2009).

    CAS  Article  Google Scholar 

  17. 17

    IMS MIDAS (2008).

  18. 18

    Lewis, D. et al. Morgan Stanley report (Morgan Stanley, April 2009).

    Google Scholar 

  19. 19

    Arnold, C. et al. Credit Suisse report (Credit Suisse, July 2009).

    Google Scholar 

Download references

Author information

Affiliations

Authors

Ethics declarations

Competing interests

J.M.B. has research contracts with Biogen Idec, Merck Serono and Pfizer, and holds consulting positions at Roche, Crescendo Biosciences and Centocor.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pappas, D., Bathon, J., Hanicq, D. et al. Golimumab. Nat Rev Drug Discov 8, 695–696 (2009). https://doi.org/10.1038/nrd2982

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing